Company: CERO
Filing Date: 2025-06-17
Form Type: 8-K
Source: 0001213900-25-054961
Chunk: 0

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-06-17
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events.

On
June 17, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “ Company”), issued a press release announcing
that the U. S. Food and Drug Administration had granted the Company’s Orphan Drug Designation for the Company's lead drug candidate
CER-1236, for the treatment of acute myeloid leukemia. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current
Report on Form 8-K.

Item 9.01
Financial Statements and Exhibits.

(d) Exhibits

  Exhibit      Description                                                                   
      No.                                                                                    
     99.1      Press release, dated June 17, 2025.                                           
 ─────────────────────────────────────────────────────────────────────────────────────────────
      104      Cover Page Interactive Data File (embedded within the Inline XBRL document).  

SIGNATURE

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

  Dated: June 17, 2025      CERO THERAPEUTICS                               
                            HOLDINGS, INC.                                  
 ────────────────────────────────────────────────────────────────────────────
                            By:                    /s/                      
                            Name:                  Chris Ehrlich            
                            Title:                 Chief Executive Officer